Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib, Toripalimab and SRT in LARC
NCT05763927Phase 2Unknown
- Sponsor
- West China Hospital of Sichuan University
- Start
- Sep 2022
- Primary completion
- Oct 2024
- Modality
- Fragment-Derived Small Molecules, Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fruquintinib and toripalimab in rectal cancer, sponsored by West China Hospital of Sichuan University. Primary endpoint: Pathological Complete Response. Status: unknown.
02
Drugs
fruquintinibtoripalimab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT05763927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05763927.